Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
- 289 Downloads
To the Editor,
Lamb and Syed  reviewed the pharmacological and clinical properties of LY2963016 insulin glargine 100 U/ml (LY insulin glargine), a biosimilar to insulin glargine 100 U/ml (Gla-100, Lantus®). They considered several studies that compared LY insulin glargine and Gla-100 and concluded that the efficacy and safety profiles of these two insulins are similar.
I would like to draw to readers’ attention that, while the authors refer to Gla-100 as the reference insulin, this definition is only provided within the abstract and introduction. The main body of the article simply referred to “reference insulin glargine,” and I believe this may create some confusion. Indeed, since 2015, in most countries, a different formulation of insulin glargine has also been available in addition to insulin glargine 100 U/ml (Gla-100). This formulation is insulin glargine 300 U/ml (Gla-300), which has different characteristics (a prolonged duration of action, more even steady-state pharmacokinetic/pharmacodynamic  profile, and lower incidence of hypoglycemia [3, 4] than Gla-100).
To avoid potential misinterpretation by the reader on the similarities of LY insulin glargine and the reference molecule, I believe it should be clarified that Gla-100 is the “reference insulin” in the studies reviewed, not Gla-300.
Compliance with Ethical Standards
No funding was received for the preparation of this letter.
Conflict of interest
Riccardo Perfetti is a Sanofi employee and shareholder.
- 4.Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–67.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.